Cytokines in multiple sclerosis: from bench to bedside

Pharmacol Ther. 2005 May;106(2):163-77. doi: 10.1016/j.pharmthera.2004.11.007. Epub 2005 Jan 11.

Abstract

Cytokines play an important role in the pathogenesis of inflammatory diseases including multiple sclerosis (MS). Experimental models have played a critical role in unraveling the roles of individual cytokines in this disease; however, these studies occasionally yield conflicting results, highlighting the complex role cytokines play in the disease process. Efforts to modulate cytokine function in MS have shown that effective treatments alter cytokine expression in the central nervous system (CNS) and in activated mononuclear cells, indicating that they are important therapeutic targets. In this review, we will summarize the current knowledge on the role of cytokine pathways in MS and what we learned from investigation of its animal model: experimental autoimmune encephalomyelitis (EAE).

Publication types

  • Review

MeSH terms

  • Adult
  • Animals
  • Cytokines / adverse effects
  • Cytokines / pharmacology
  • Cytokines / physiology*
  • Demyelinating Diseases / etiology*
  • Demyelinating Diseases / physiopathology
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Janus Kinase 1
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / etiology*
  • Multiple Sclerosis / physiopathology
  • Peptides / therapeutic use
  • Protein-Tyrosine Kinases / physiology*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology

Substances

  • Cytokines
  • Immunosuppressive Agents
  • Peptides
  • Glatiramer Acetate
  • Protein-Tyrosine Kinases
  • JAK1 protein, human
  • Janus Kinase 1